Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05799118 · ClinicalTrials.gov registry record

Study of the Role of Genetic Modifiers in Hemoglobinopathies

A clinical trial of Sickle Cell Disease and Hemoglobinopathies, sponsored by Cyprus Institute of Neurology and Genetics.

Recruiting
Registry status
30,000
Enrollment target
20
Study locations

NCT05799118 is a study of Sickle Cell Disease and Hemoglobinopathies that is actively recruiting participants, run by Cyprus Institute of Neurology and Genetics. The registered enrollment target is 30,000 participants, above the 152-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (19637% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05799118, a study of Sickle Cell Disease and Hemoglobinopathies, is actively recruiting participants, sponsored by Cyprus Institute of Neurology and Genetics.

RECRUITING
Registry status
30,000 participants
Enrollment target
20
Study locations

Study Summary

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Conditions Studied

Sickle Cell Disease Hemoglobinopathies Thalassemia, Beta Thalassemia Alpha

Interventions

  • GENETIC GWAS

Study Locations (20)

Other

  • Lucrecia Paím Maternity - Luanda
  • University of Buenos Aires - Buenos Aires
  • University Hospitals Leuven - Leuven
  • Universiti Brunei Darussalam - Brunei
  • Larnaca General Hospital - Larnaca
  • Limassol General Hospital - Limassol
  • Archbishop Makarios III Hospital - Nicosia
  • Paphos General Hospital - Paphos
  • Centre Hospitalier Monkole - Kinshasa
  • Rigshospitalet - Copenhagen
  • Hippokrateio Hospital of Athens - Athens
  • Laiko General Hospital - Athens
  • National and Kapodistrian University of Athens - Athens
  • General Hospital of Larissa - Larissa
  • Emek Medical Centre - Afula
  • University of Turin - Turin
  • Ampang Hospital - Ampang
  • Universiti Kebangsaan Malaysia - Bangi
  • Universiti Sains Malaysia - Kota Bharu

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30,000 participants
Start Date 2022-10-01
Est. Completion 2027-09-30

Sponsor

Cyprus Institute of Neurology and Genetics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05799118

The ClinicalTrials.gov registry entry for NCT05799118 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 152-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (19637% higher). The listed sponsor is Cyprus Institute of Neurology and Genetics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which GWAS is the first listed.

NCT05799118 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05799118 about?

NCT05799118 is a clinical study titled "Study of the Role of Genetic Modifiers in Hemoglobinopathies". This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

What is the current status of trial NCT05799118?

This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2022-10-01. Estimated completion is 2027-09-30.

What conditions does trial NCT05799118 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathies, Thalassemia, Beta, Thalassemia Alpha.

What interventions are being tested in trial NCT05799118?

The interventions under investigation include: GWAS (GENETIC).

Who is sponsoring clinical trial NCT05799118?

This trial is sponsored by Cyprus Institute of Neurology and Genetics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05799118 being conducted?

This trial has 20 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Hemoglobinopathies

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.